Moody’s forecasts slow growth over the next 12-18 months and said companies with product-specific challenges or products used for elective procedures are more likely to buy back shares and pursue acquisitions. Orthopedic manufacturers and cardiac device makers are most likely to experience slow growth.
Related Articles on Medical Devices:
FDA Approves Intuitive Surgical’s Single-Site Instrumentation for Gallbladder Surgery
Surgical Implant Mimics Periosteum to Heal Bone Injuries
Clemson University Bioengineering Lab to Study Surgical Implants, Joint Replacements
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
